Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma

Carcinoma, Bronchogenic

Bronchial Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles.

100 patients with stage IV EGFR / ALK wild-type NSCLC (squamous cell carcinoma patients do not need to be detected) who received anti-PD-1 (pabolizumab) treatment combined with chemotherapy as the first-line treatment were enrolled in the center. Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles. At the same time, plasma samples were collected at key nodes until the patient's progress.

pabolizumab

nafulizumab

wang jia lei, doctor

wang jia lei, DOCTOR

To detect the difference of PD-L1 and miRNA expression profiles of exosomes in NSCLC patients before and after immunotherapy, and to explore the potential of plasma exosomes PD-L1 and miRNAs as biomarkers to predict the therapeutic effect of NSCLC on anti-PD-1 / PD-L1.

Prediction of Immunotherapeutic Effect of Advanced Non-small Cell Lung Cancer

Study on the Prediction of Immunotherapeutic Effect of Advanced Non-small Cell Lung Cancer by Detection of Plasma Exosomes

detect the difference of PD-L1 expression profiles of exosomes in NSCLC patients before and after immunotherapy

detect the difference of miRNA expression profiles of exosomes in NSCLC patients before and after immunotherapy

Fudan University

Principal Investigator

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Prediction of Immunotherapeutic Effect of Advanced Non-small Cell Lung Cancer	NCT04427475	NSCLC Patients	pabolizumab nafulizumab	18 Years -	Fudan University
Prediction of Immunotherapeutic Effect of Advanced Non-small Cell Lung Cancer	NCT04427475	NSCLC Patients	pabolizumab nafulizumab	18 Years -	Fudan University

Spots Global Cancer Trial Database for nafulizumab

Every month we try and update this database with for nafulizumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for nafulizumab

Every month we try and update this database with for nafulizumab cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for nafulizumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.